

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No. 46216

In re patent application of

SASAKI et al.

Serial No. 09/700,187

Filed: November 13, 2000

For: LIGHT-REPRESSIBLE PROMOTERS

Group Art Unit: 1638

Examiner: Helmer, Georgia L.

RECEIVED

MAR 03 2003

TECH CENTER 1600/2900

TRANSMITTAL OF RESPONSEAssistant Commissioner for Patents
Washington, D.C. 20231


Sir:

Transmitted herewith is an Response in the above-captioned application. The fee has been calculated as shown below. (Small entity fees indicated in parentheses.)

CLAIMS AS AMENDED							
(1)	(2)	(3)	(4)	(5)	(6)	(7)	
	Claims Remaining After Amendment		Highest Number Previously Paid For	Extra Claims	Rate	Fee	
Total Claims	36	-	36		18.00	\$0	
(Small Entity)					(9.00)		
Independent claims	4	-	4		84.00	\$0	
(Small Entity)					(42.00)		
Multiple Dependent	0	-	0	0	280.00	0	
(Small Entity)					(140.00)		
Extension of Time	One Month		Two Months	Three Months			
Fee	\$110		\$410		\$930	\$0	
(Small Entity)	(\$55)		(\$205)		(\$465)	0	
Total						\$0	

The above fees are believed to be correct. However, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 50-0687 under the above Attorney Docket Number for which purpose this paper is submitted in duplicate.

Respectfully submitted,



Paul E. White, Jr.
Reg. No. 32,011
Tel. No. 202-261-1050
Fax No. 202-887-0336

Date: February 27, 2003

Manelli Denison & Selter, PLLC
2000 M Street, N.W.
Suite 700
Washington, D.C. 20036-3307
202.261.1000

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

8 27 2003
TRADE MARK
The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

1. This application clearly fails to comply with the requirements of 37 CFR 1.821 - 1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.

2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).

3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).

4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached marked-up copy of the "Raw Sequence Listing."

5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).

6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).

7. Other: Applicant must identify all sequences by a sequence identifier. Sequence Identifier Nos
Applicant must provide: need to be given to all primers and the

Primer identified with that SID # ~~as~~ in the Specification,
 An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification
 A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)

RECEIVED

MAR 03 2003

V TECH CENTER 1600/2900

or questions regarding compliance with these requirements, please contact:

or Rules Interpretation, call (703) 308-1123
or CRF submission help, call (703) 308-4212
or PatentIn software help, call (703) 308-6856

For example, the primers on p 30 of the specification
have no SID #s.
Please return a copy of this notice with your response

DR. GEORGIA HELMER

703-308-7023